Quick Dispatch:
Your surpass cvot tirzepatide results Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass cvot tirzepatide results Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes ships.
Need Help?
Questions about surpass cvot tirzepatide results Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass cvot tirzepatide results Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes in your area.
02188-7/asset/2a04fe44-9b50-44db-92c6-1be9af993976/main.assets/gr2_lrg.jpg "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial")
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
29.05
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
23.28
Should Diabetes Management be More Adipose-Centric?
20.10
Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study
21.80
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme - Pedersen
25.07
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
27.09
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
29.85
